Peter J. Maimonis, Ph.D. has been appointed vice president of biomarker development at Biothera and will lead the development and commercialization of assays for the company’s Phase III cancer immunotherapy, Imprime PGG. Dr. Maimonis previously held senior positions with various pharmaceutical and diagnostic companies, including senior director, Cancer Cell Biology at On-Q-ity, vice president of Biology R&D at Decision Biomarkers, and associate director for Oncology Research at Bayer Health Care.
“For the past quarter century Dr. Maimonis has focused on the discovery and development of oncology biomarkers, companion diagnostics and assays,” said Dan Conners, president of Biothera’s Pharmaceutical Group. “His expertise is a perfect fit for Biothera as we advance the science of the predictive biomarker for Imprime PGG.”
Biothera Names Biomarker Development VP
By Kristin Brooks
Published January 28, 2014
blog comments powered by Disqus